Thalidomide belongs to a class of drugs that target the 3′-untranslated region (UTR) of tumor necrosis factor alpha (TNF-α) mRNA, inhibiting TNF-α production, and have multipotent and pleiotropic effects, thus being tested to treat neuroinflammation in neurodegenerative diseases (Jung et al., 2019). The gene discussed is TNF; the disease is neurodegenerative disease.